于永生 副研究员-高研院
硕士招生类型：学术型
硕士招生专业：妇产科学
博士招生类型：无
博士招生专业：无
所在院系：附属第一妇婴保健院
联系方式：yongshengyu@tongji.edu.cn /yongshengy@126.com
课题组链接：
研究方向
主要任职
科研业绩

肿瘤靶向治疗;多肽、蛋白化学生物学;肿瘤免疫 Targeted therapy for cancer; Chemical biology of peptide and protein; Cancer immunotherapy
美国化学学会(ACS)会员
中国生物医学工程学会会员
SCI专业杂志Lead客座编辑 (Technology in Cancer Research & Treatment)
1.2017-至今 同济大学附属第一妇婴保健院 副研究员；
2. 2015-2017香港中文大学 博士后；
3.2012-2015 香港中文大学 博士
Member of the American Chemical Society (ACS) and Chinese Society of Biomedical Engineering (CSBME)：
1.Since 2017 First Maternity and Infant Hospital Affiliated to Tongji University Associate Professor；
2. 2015-2017 The Chinese University of Hong Kong Postdoctoral Fellow；
3. 2012-2015 The Chinese University of Hong Kong Ph.D
主持科研项目：
1. 国家自然科学基金；
2. 上海市“浦江”人才计划 ；
3. 上海市“科技创新行动计划”港澳台科技合作项目；
4. 上海市卫计委科研课题-青年项目 ；
5. 中央高校基本科研业务专项 ；
6. 同济大学青年优秀人才培养行动计划
SCI第一或通讯作者 First or corresponding author:
1. Gao J, Yu YS(共一), Zhang YY, et al., EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma, Biomaterials,2012, 33: 270-82；
2. Gao J, Chen HW, Yu YS(共一), et al., Inhibition of hepatocellular carcinoma growth using immunoliposomes for codelivery ofAdriamycin and ribonucleotide reductase M2 siRNA. Biomaterials, 2013, 34:10084-98；
3. Yu YS, Xia J. Affinity-Guided Protein Conjugation：the Trilogy of Covalent Protein Labeling, Assembly and Inhibition. Science China-Chemistry, 2016,07:853-861；
4. Yu YS, Li SD, Wang K, Wan XP. A PDZ protein MDA-9/Syntenin: as a target for cancer therapy. Computational and Structural Biotechnology Journal, 2019, 17,136-141；
5. Yu YS, Liu M, Ng TT, et al.,PDZ-reactive peptide activates Ephrin-B reverse signaling and inhibits neuronal chemotaxis. ACS Chemical Biology, 2016, 11:149-158；
6. Yu YS, Nie YY, Feng Q, et al.,Targeted covalent inhibition of Grb2?Sos1 interaction through proximity-induced conjugation in breast cancer cells. Molecular Pharmaceutics, 2017,14:1548-1557；
7. Yu YS,Wang JP, Liu JH, Ling DS, Xia J. Functional assembly of protein fragments induced by spatial confinement. PLoS One, 2015, 10:e**；
8. Liu JH, Qu JL, Zhou WD, Huang XJ, Xia J, Yu YS*(通讯作者). Syntenin-targeted peptide blocker inhibits progression of cancer cells. European Journal of Medicinal Chemistry, 2018,154:354-366；
9. Hou JJ, Tan YY, Su C, Wang T, Gao Z, Song D, Zhao J, Liao Y, Liu X, Jiang Y, Feng Q, Yu YS*(通讯作者). Inhibition of FAK enhances 5-FU chemosensitivity to gastric carcinoma via the MAPK-ERK and p53 signaling pathways. Computational and Structural Biotechnology Journal, 2020,18:125-136；
10. Huang Y, Feng Q, Jiang H, Zhou W, Chen J, Gao J, Wang K, Wan X, Yu YS*(通讯作者). Mimicking the Endometrial Cancer Tumor Microenvironment to Reprogram Tumor-Associated Macrophages in Disintegrable Supramolecular Gelatin Hydrogel. International Journal of Nanomedicine. 2020,15:4625-4637；
11. Jiang H, Li L, Zhang J, Wang Y, Hou J, Yu YS*(通讯作者). MiR-101-3p and Syn-Cal14.1a Synergy in Suppressing EZH2-Induced Progression of Breast Cancer. OncoTargets and Therapy, 2020, 13:9599-9609；
12. Jiang H, Li L, Zhu S, Hou J, Yu YS*(通讯作者).Carcinogenic roles and therapeutic effects of EZH2 in gynecological cancers.Bioorganic medicinal chemistry. 2020,28(7):115379；
13. Jiang H, Ding CF, Zhou Q, Yu YS*(通讯作者). Proximity-induced Covalent Peptide for Selective Inhibition of MDA-9 in Breast Cancer Cells. Basic & clinical pharmacology & toxicology, 2020,127-S1 拥有多项国家发明专利(第一发明人)